ACM
BCRX icon

Aster Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aster Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$45 – 861
2026
Q1 		$45 Sell
6
-888
-99% -$6.9K ﹤0.01% 807
2025
Q4 		$6.97K Buy
+894
New +$6.46K ﹤0.01% 815
2025
Q2 		– Sell
-3,985
Closed -$34.3K – 1062
2025
Q1 		$34.3K Buy
3,985
+3,836
+2,574% +$30.9K 0.01% 892
2024
Q4 		$1.12K Sell
149
-3,489
-96% -$26.5K ﹤0.01% 1006
2024
Q3 		$27.6K Buy
+3,638
New +$27.7K 0.01% 623

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Aster Capital Management's BCRX Position: Q2 2026 in Review

Aster Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 6 shares — an estimated $45 sold.

Aster Capital Management first reported a position in BCRX in Q3 2024 and held it in 5 quarters. The position peaked at $34.3K in Q1 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Aster Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 6 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $45.
  • Aster Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Aster Capital Management's BioCryst Pharmaceuticals position peaked at $34.3K in Q1 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.